Canderova Tablet 20/32 mg
Rosuvastatin Calcium 20.8mg · Candesartan Cilexetil 32mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
MFDS item code 202008713 · Approved 2020.12.11
Treatment of hypertension and heart failure; improvement of dyslipidemia; suppression of atherosclerosis progression and cardiovascular risk
This medication is used in patients who require the combined administration of the two components, Candesartan Cilexetil and Rosuvastatin. Candesartan Cilexetil is mainly used for patients with essential hypertension and heart failure, particularly effective in those with impaired left ventricular systolic function who have not responded adequately to ACE inhibitors or have poor tolerance. Rosuvastatin is used in patients with hypercholesterolemia and dyslipidemia in conjunction with dietary and exercise therapy or as an adjunct, reducing blood cholesterol levels and delaying the progression of atherosclerosis. It also helps to reduce the risk of stroke, myocardial infarction, and arterial revascularization in patients at high risk of cardiovascular disease. Thus, the combined administration of the two drugs is used to effectively manage hypertension and dyslipidemia, reducing the risk of cardiovascular disease.
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of 2 weeks or more, up to a maximum of 32 mg once daily, depending on the patient's tolerability. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg per day. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Essential hypertension: The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger. Heart failure: The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger.
This medication may cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, and should be discontinued immediately upon confirmation of pregnancy. This medication is contraindicated in patients with a known allergy to it, those with severe liver function impairment, and those with certain genetic lactase metabolism disorders. Special caution should be taken in elderly patients, those with impaired kidney function, and those with hyperkalemia, and regular blood tests and liver function tests should be performed under a doctor's advice. If symptoms such as myalgia or muscle weakness occur, immediate consultation with a physician is necessary, and in severe cases, it may be required to discontinue the medication. Interactions may occur if taken with other antihypertensive medications or certain lipid-lowering drugs; therefore, it is essential to inform the doctor or pharmacist of any other medications being taken. Caution is warranted as dizziness or fatigue may occur when driving or operating machinery. Women who could become pregnant should use appropriate contraception before taking this medication, and breastfeeding women are advised to avoid it. In cases of overdose, seek medical attention immediately, and since there is no specific antidote, treatment will be symptomatic. The safety and efficacy of this medication in children have not been established, thus it is not recommended. Keep the medication out of reach of children and do not transfer it from its original container to another.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. It is recommended to maintain the storage temperature between 1 degree and 30 degrees Celsius.
Pink round film-coated tablet
30 tablets (10 tablets/PTP X 3) - 30 tablets/PTP [30 tablets (10 tablets/PTP X 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Rosuvastatin Calcium 20.8mg · Candesartan Cilexetil 32mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
AlboGen Korea Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Candesartan Cilexetil 32mg
Tablet · Prescription medication · Combination
Albogen Korea Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 16mg
Tablet · Prescription medication · Combination
Alvogen Korea Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Alvogen Korea Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 16mg
Tablet · Prescription medication · Combination
Hanin Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Hanin Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Candesartan Cilexetil 8mg
Tablet · Prescription medication · Combination
Hanin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.